Despite extensive knowledge of the molecular components involved in HlV-1 transcriptional regulation, there is a critical need to understand how these components interact kinetically to form a regulatory 'switch'that mediates establishment, maintenance, and reactivation of HIV-1 latency at the single-cell level. Our long-term goal is to develop interventions to inhibit or purge latent HIV reservoirs, or alternatively, direct all replicating HIV to enter a latent state. The objective of this particular project is to quantitatively analyze the gene-regulatory circuitry underlying HIV latency and to quantify the effects of drugs on HIV's gene-regulatory circuitry in different primary-cell latency models. Our rationale for this project is that quantitative single-cell imaging of HIV gene expression will enable us to elucidate the gene-regulatory circuitry that controls latency in primary cells just as we were able to eluciate key aspects of the HIV latency circuitry in Jurkat cells. We pioneered the use of single-cell imaging approaches to study the role of stochastic noise in HIV gene expression and our analysis has elucidated that HlV-1 utilizes transcriptional positive feedback via Tat to amplify stochastic fluctuations in HIV gene expression and thereby establish a probabilistic molecular 'switch'between proviral latency and active infection (Weinberger et al. Cell 2005). that host SirT1 dampens fluctuations in Tat feedback (Weinberger &Shenk, PLoS Biology 2007), and that manipulating the feedback strength, in the J-lat latency model, can bias infected cells towards maintaining latency and not reactivating (Weinberger et al. Nature Genetics, 2008). We will employ microfluidic approaches and quantitative time-lapse imaging of HIV gene-expression to quantitatively compare the single-cell level effects of diverse drug candidates upon induction of latent gene expression in different primary-cell models. The resulting analysis will allow different drug candidates to be quantitatively compared in terms of their effect on gene expression in single cells and will guide molecular analyses in other projects within the collaboratory.

Public Health Relevance

The HlV-1 proviral latent reservoir remains the most problematic obstacle facing viral eradication from the patient. Understanding how HIV enters, maintains, and breaks latency is critical to designing effective interventions that can eradicate HIV. This project will develop models of HIV latency and test the effect of drugs intended to inhibit HIV latency.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI096113-02
Application #
8514788
Study Section
Special Emphasis Panel (ZAI1-JBS-A (M1))
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$136,543
Indirect Cost
$32,695
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
White, Cory H; Beliakova-Bethell, Nadejda; Lada, Steven M et al. (2018) Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol 9:603
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Jiang, Guochun; Nguyen, Don; Archin, Nancie M et al. (2018) HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest 128:1190-1198
Dubé, Karine; Dee, Lynda; Evans, David et al. (2018) Perceptions of Equipoise, Risk-Benefit Ratios, and ""Otherwise Healthy Volunteers"" in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. J Empir Res Hum Res Ethics 13:3-17
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Honeycutt, Jenna B; Liao, Baolin; Nixon, Christopher C et al. (2018) T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest 128:2862-2876
Power, Jennifer; Westle, Andrew; Dowsett, Gary W et al. (2018) Perceptions of HIV cure research among people living with HIV in Australia. PLoS One 13:e0202647
Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93
Dubé, Karine; Taylor, Jeff; Sylla, Laurie et al. (2017) 'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States. PLoS One 12:e0170112

Showing the most recent 10 out of 221 publications